help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foster, C. M.
Right arrow Articles by Cutler, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foster, C. M.
Right arrow Articles by Cutler, G. B., Jr

Journal of Clinical Endocrinology & Metabolism, Vol 59, 801-805, Copyright © 1984 by Endocrine Society

ARTICLES

Variable response to a long-acting agonist of luteinizing hormone- releasing hormone in girls with McCune-Albright syndrome

CM Foster, F Comite, OH Pescovitz, JL Ross, DL Loriaux and GB Cutler Jr

Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. Feuillan, K. Calis, S. Hill, T. Shawker, P. G. Robey, and M. T. Collins
Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2100 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. B. Nunez, K. Calis, G. B. Cutler Jr., J. Jones, and P. P. Feuillan
Lack of Efficacy of Fadrozole in Treating Precocious Puberty in Girls with the McCune-Albright Syndrome
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5730 - 5733.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Gromoll, C.-J. Partsch, M. Simoni, V. Nordhoff, W. G. Sippell, E. Nieschlag, and B. B. Saxena
A Mutation in the First Transmembrane Domain of the Lutropin Receptor Causes Male Precocious Puberty
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 476 - 480.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society